Inmune Bio Inc Stock Price, News & Analysis

INmune Bio, Inc. (NASDAQ: INMB) reported its Q2 2021 financial results and provided a business update on August 4, 2021. The company is progressing towards a Phase 2 clinical trial of XPRO™ in mild Alzheimer’s patients, aiming to start by year-end. Recent financial highlights include a net loss of $6.7 million and increased R&D expenses of $4.5 million. The company raised $51.9 million in July 2021, securing funding for its upcoming trials. Notably, the first patient has been treated in the Phase 1 trial of INKmune for high-risk myelodysplastic syndrome.

INmune Bio, Inc. (NASDAQ: INMB) will host a conference call on August 4, 2021, at 4:30 PM ET to discuss its second-quarter results for the period ending June 30, 2021. The call will provide a corporate update, and participants can join by dialing in 5-10 minutes early. A transcript and replay will be available shortly after the call. The company focuses on developing treatments utilizing the innate immune system, with platforms targeting conditions like COVID-19, cancer, Alzheimer’s, and chronic inflammation.

INmune Bio announced the design of a Phase 2 clinical trial of XPro^TM for mild Alzheimer’s disease (AD), involving 168 patients over six months. The trial aims to assess the impact of reducing neuroinflammation on cognition. Preliminary data from a Phase 1b study indicated improvements in white matter metrics and biomarkers of neuroinflammation with a 1.0 mg/kg dose. A recent $40 million financing will support this Phase 2 trial, which is set to start in Q4 2023, with data expected in 2H2023.

INmune Bio (NASDAQ: INMB) has acquired LUMICKS' z-Movi® Cell Avidity Analyzer to enhance its Natural Killer (NK) Cell Priming Platform, INKmune®. This cutting-edge technology allows INmune to measure the efficacy of NK cells against tumors by analyzing the avidity of cell interactions. Preliminary data suggests that improved NK cell avidity may enhance tumor cell killing. This acquisition aims to streamline potency screening and establish biomarkers, accelerating drug development for cancer therapies.

INmune Bio, Inc. (NASDAQ: INMB) announced plans to commence a Phase 2 study of XPro1595 for Alzheimer’s disease by the end of 2021, following promising Phase 1b results. The upcoming study aims to further evaluate the drug's efficacy in reducing neuroinflammation, which has shown potential in improving biomarkers related to neurodegeneration. The company will present findings at the Alzheimer’s Association International Congress 2021, detailing the positive outcomes from its earlier study.

INmune Bio, Inc. (NASDAQ: INMB) announced a registered direct offering of 1,818,182 shares at $22.00 per share, raising approximately $40 million. The offering, set to close on July 16, 2021, is facilitated by A.G.P./Alliance Global Partners. Proceeds will support working capital, corporate purposes, and advancement of product candidates, particularly the Phase 2 trial of XPro1595 for Alzheimer’s disease, expected to start by year-end 2021. This funding aims to fully support the Alzheimer’s Phase II program.

INmune Bio announces the initiation of its first patient treatment in a Phase 1 clinical trial of INKmune, targeting high-risk myelodysplastic syndrome (MDS). This trial will assess safety, tolerability, and clinical response in MDS patients, a serious condition with no known cure. INKmune aims to enhance the activity of dysfunctional natural killer (NK) cells in patients. Initial findings indicate promising potential for treating MDS and possibly solid tumors. The Phase 1 study will enroll nine patients under a 3x3 dose escalation protocol.

On June 14, 2021, INmune Bio (NASDAQ: INMB) announced a $15 million credit facility with Silicon Valley Bank to fund the buyout of an option held by Xencor, Inc. for $18.3 million. This move eliminates the potential dilution of approximately 2.1 million shares. INmune has made significant progress in developing XPro1595, a treatment for neuroinflammation in conditions like Alzheimer’s. The company is focused on launching Phase 2 trials for XPro1595 later this year, following positive data earlier this year regarding its Alzheimer's application.

INmune Bio (NASDAQ: INMB) has received USAN approval for the generic name Pegipanermin for its lead candidate XPro1595. CEO RJ Tesi stated that this milestone marks the transition from experimental to advanced development, with plans for Phase 2 trials targeting Alzheimer’s disease and Treatment Resistant Depression. The company previously reported positive Phase 1b data showing reduced biomarkers of neuroinflammation in Alzheimer's patients. Pegipanermin utilizes a unique TNF neutralization technology, differentiating it from existing therapies.